TuHURA Biosciences Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -266.7% | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | -46.7% | +345.3% | -18.6% | -39.2% | -20.3% | -0.4% | +52.1% | +5.9% | +4.1% | +19.7% | – | |
| – | – | – | -17.7% | -63.3% | – | – | -1.2% | +15.9% | +20.4% | +42.5% | -23.4% | – | |
| – | -64.3% | -200.0% | – | – | +1,299.9% | -77.1% | +280.8% | -420.8% | – | -34.0% | -568.8% | – | |
| – | – | -100.0% | – | – | +29.7% | +99.4% | -87.0% | -99.9% | +696,150.0% | +75.4% | +180.4% | – | |
| – | – | – | – | – | -84.2% | +39.8% | -86.4% | – | -103.4% | +75.4% | +180.4% | – | |
| – | +0.0% | +0.0% | -100.0% | – | – | – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -117.4% | – | – | |
| – | +399,550.0% | – | +179.7% | +137.1% | -111.4% | -84.4% | – | -39.4% | +23.4% | +9.7% | -51.4% | – | |
| – | – | – | +885.6% | +68.7% | -152.4% | – | – | -353.6% | – | +190.3% | -298.0% | – | |
| – | – | -266.7% | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.